US Centres for Medicare and Medicaid Services (CMS) has said it will pay for any COVID-19 vaccine that is authorised or approved by the US Food and Drug Administration to allow for "broad vaccine access and coverage for all Americans.", CNN reported on Thursday.
Also, the agency announced it will help cover a larger portion of the cost of new COVID-19 treatments that may be coming down the pipeline for Medicare recipients.
CMS administrator, Seema Verma, was quoted as saying during a briefing on 28 October: "There are several vaccines in Phase 3 trials, production and distribution plans are well underway, and CMS is doing its part by laying the essential groundwork for coverage and payment when a vaccine does arise. It'll be widely available and accessible to seniors and every American."
She added that while the US federal government is paying for the vaccine, insurers including Medicare, Medicaid and private plans must cover the cost of administering it.
Akeso agrees clinical trial collaboration with INOVIO
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Frontage Laboratories acquires Teddy Clinical Research Laboratory in China
Allergy Therapeutics reports positive biomarker data from PROTECT trial
HUTCHMED doses first patient in global trial of ATTC candidate HMPL-A580
Ensorcell adds new senior leadership team members
Sino Biological launches 2026-2027 Northern Hemisphere influenza vaccine strain antigens
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Lynk Pharmaceuticals reveals positive topline results from zemprocitinib Phase III clinical trial
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
Ono Pharmaceutical expands multi-target research collaboration with Congruence Therapeutics
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study
Genentech's fenebrutinib meets primary endpoint in pivotal Phase III study for multiple sclerosis
ValiRx establishes animal health subsidiary to target veterinary oncology market
FDA accepts rusfertide NDA and grants priority review for polycythemia vera